Bergenbio ASA, of Bergen, Norway, said the first patient was dosed in a phase II trial evaluating its lead candidate, BGB-324, in combination with Keytruda (pembrolizumab, Merck & Co. Inc.) in patients with previously treated advanced non-small-cell lung cancer who have progressive disease.